Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine

Pharmacogenetics

Volumn 8, Issue 2, 1998, Pages 181-185

  Sachse, Christoph ^a   Brockmöller, Jürgen ^a   Hildebrand, Michael ^b   Müller, Katrin ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

CYP2D6 gene duplication; Debrisoquine polymorphism; Human cytochrome P450 2D6

Indexed keywords

DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; NORMAL HUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0031960093     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199804000-00010     Document Type: Article

References (13)

1. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32:210-258.
2. Broly F, Gaedigk A, Heim M, Eichelbaum M, Mörike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10:545-558.
3. Daly AK, Brockmöller J. Broly F, Eichelbaum M, Evans WE, Gonzalez FJ et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
4. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336:529-532.
5. Hildebrand M, Seifert W, Reichenberger A. Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 1989; 36:315-318.
6. Johansson I, Lundqvist E, Dahl M-L, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996; 6:351-355.
7. Kerb R, Brockmöller J. Analysis of cytochrome P-4502D6 genotype and phenotype in 390 Caucasians. Naunyn Schmiedeberg's Arch Pharmacol 1992; 345 (suppl), R10.
8. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996; 392:30-34.
9. Løvlie R, Daly AK, Idle JR, Steen VM. Characterization of the 16 + 9 kb and 30 + 9 kb CYP2D6 XbaI haplotypes. Pharmacogenetics 1997; 7:149-152.
10. Marez D, Legrand M, Sabbagh N, Lo Guidice J-M, Spire C, Lafitte J-J et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.
11. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
12. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988; 85:5240-5243.
13. Steen VM, Molven A, Aarskog NK, Gulbrandsen A-K. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of the human cytochrome P450 CYP2D6 gene. Hum Mol Genet 1995; 4:2251-2257.